SCHEMBL4716213

SCHEMBL4716213

O=C(O)Cn1c(CCc2ccc(C(F)(F)F)cc2)nc(=O)c2c1CCC2

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ EGLN1 Q9GZT9 1/20 0.45
▸ FABP4 P15090 2/20 0.44
▸ LMNA P02545 2/20 0.43
▸ PLA2G7 Q13093 10/20 0.43
▸ CYP3A4 P08684 2/20 0.43
▸ CYP2D6 P10635 2/20 0.43
▸ TSHR P16473 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ GLA P06280 1/20 0.40
▸ CASP1 P29466 1/20 0.40
▸ CASP7 P55210 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ HDAC6 Q9UBN7 1/20 0.40
▸ AKR1B10 O60218 1/20 0.38
▸ AKR1B1 P15121 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4717562 0.88 PLA2G7 (0.49) FABP4LMNAPLA2G7CYP3A4CYP2D6
SCHEMBL4712838 0.87 PLA2G7 (0.41) EGLN1LMNAPLA2G7TSHRNPSR1
SCHEMBL4712441 0.87 KMT2A (0.48) FABP4LMNAPLA2G7TSHRKDM4E
SCHEMBL4716091 0.86 KMT2A (0.43) LMNAPLA2G7CYP3A4CYP2D6TSHR
SCHEMBL4718234 0.86 HSD17B10 (0.43) FABP4LMNAPLA2G7KDM4EMEN1
SCHEMBL4715559 0.85 PLA2G7 (0.40) EGLN1FABP4LMNAPLA2G7CYP3A4
SCHEMBL4716410 0.83 FABP4 (0.44) FABP4LMNAPLA2G7KDM4EMEN1
SCHEMBL4713382 0.82 PLA2G7 (0.48) FABP4LMNAPLA2G7CYP3A4CYP2D6
SCHEMBL4717422 0.81 PLA2G7 (0.39) LMNAPLA2G7CYP3A4CYP2D6KDM4E
SCHEMBL4714043 0.80 FABP3 (0.45) FABP4LMNAPLA2G7KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7462620-B2 Pyrimidinone derivatives and their use in the treatment of atherosclerosis SMITHKLINE BEECHAM, PLC (GB) 2008-12-09 — — US disclosed
US-7462620-B2 Pyrimidinone derivatives and their use in the treatment of atherosclerosis SMITHKLINE BEECHAM, PLC (GB) 2008-12-09 — — US disclosed
US-7462620-B2 Pyrimidinone derivatives and their use in the treatment of atherosclerosis SMITHKLINE BEECHAM, PLC (GB) 2008-12-09 — — US disclosed
EP-1337517-B1 PYRIMIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ATHEROSCLEROSIS SMITHKLINE BEECHAM PLC (GB) 2008-11-26 — — EP disclosed
US-7169924-B2 Pyrimidinone derivatives and their use in the treatment of atherosclerosis SMITHKLINE BEECHAM PLC (GB) 2007-01-30 — — US disclosed
US-7169924-B2 Pyrimidinone derivatives and their use in the treatment of atherosclerosis SMITHKLINE BEECHAM PLC (GB) 2007-01-30 — — US disclosed
US-7169924-B2 Pyrimidinone derivatives and their use in the treatment of atherosclerosis SMITHKLINE BEECHAM PLC (GB) 2007-01-30 — — US disclosed
US-20060241126-A1 Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis ELLIOTT RICHARD L 2006-10-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241126-A1 Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis PLA2G7, PLA2G1B, PLA2G4B EGLN1 2010/4885FABP4 859/4885LMNA 410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback